S-ADHF：Sarcopenia in Patients With ADHF

Launched by GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL · Mar 1, 2024

Keywords

ClinConnect Summary

The S-ADHF clinical trial is studying a condition called sarcopenia, which is the loss of muscle mass and strength, in patients who are experiencing acute decompensated heart failure. This means their heart is struggling to pump blood effectively, leading to symptoms like shortness of breath and fatigue. The trial aims to see how sarcopenia affects the health outcomes of these patients over time, especially when they have other health issues alongside heart failure. Researchers will follow participants for up to two years to gather important information about their health and recovery.

To be eligible for this study, participants should be at least 18 years old and show signs of heart failure when they are admitted to the hospital. This could include having trouble breathing or swelling in the legs. Participants will need to agree to provide consent and be willing to attend follow-up appointments. Importantly, the study is not yet recruiting participants, so if you or someone you know might be interested, it’s good to keep an eye out for updates!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥18 years
• • 2. At least one symptom of heart failure upon admission:Dyspnea at rest or with exertion, orthopnea, paroxysmal nocturnal dyspnea or exertional fatigue.
• 3. At least two of the signs of heart failure (HF):
• • Distended jugular veins, enlarged cardiac silhouette, apex beat displacement, third heart sound, or increased jugular venous pressure/central venous pressure/pulmonary capillary wedge pressure.
• • Pulmonary edema or pulmonary congestion (rales or chest X-ray/CT evidence of pulmonary congestion).
• • Peripheral edema. Elevated B-type natriuretic peptide (\>100 pg/ml) or elevated N-Terminal Pro-Brain Natriuretic Peptide (\>300 pg/ml).
• • Willingness to provide informed consent and cooperate with the follow-up
• Exclusion Criteria:
• • 1. Unable to understand and comply with protocol or to give informed consent
• • 2. End-stage diseases other than heart failure, life expectancy \<1 year, such as malignant tumors
• • 3. Current or planned participation in a clinical trial.